

BioWin Day 2021

Wallonia, the beating heart of European health innovation



#15ybiowin

BIOWin
THE HEALTH CLUSTER OF WALLONIA

9 December 2021 - 10:00 – 17:00 CET ● 150 minutes of virtual plenary session ● 5 digital roundtables animated by our sponsors GSK, Pharmalex, PWC, Ayming, Belfius and Janssen Belgium in the afternoon ● 15 days of online matchmaking ● Virtual exhibition

[REGISTER NOW](#)

[DISCOVER THE PROGRAM](#)

AFTERNOON ROUNDTABLES

13:00-14:00 – The science of the immune system – building a healthy future

animated by



The topic for this round table focuses on the science of the immune system in order to build a healthy future in the region and the country. Immunology is core in many different disease areas (vaccinology, oncology, personalized medicines,...). The expertise and understanding of the complexity of the immune system is key, as it can help accelerate the development of vaccines to prevent disease, or medicines against diseases that are immune-mediated (eg oncology, cell & gene therapy,...) to stay ahead of disease for patients.

The panel will deep dive into several important strategic objectives, from the perspective of experts representing the government, academia, and the pharmaceutical industry. Some elements that will be discussed are how the funding for research in immunology could be increased, how to strengthen collaboration and build bridges between academia and pharma industry, how talents can be developed, recruited, retained and how to help them keep up with the evolving digital requirements.

With the participation of the top experts representing different stakeholders of the strong biopharma ecosystem, this round table will bring concrete and complementary insights on how Wallonia and Belgium can continue to strengthen their expertise in the field of immunology.

Speakers:

Nicolas Pire, Chief of cabinet Minister Willy Borsus, VP of Wallonia, Minister of Economy, External Trade, Research & Innovation, Digital, Agriculture, center of excellences, ...

Prof Fabrice Bureau, Vice-Rector - ULiège

Jan Van der Goten, Head of the Janssen Pharmaceutical Campus & Strategic Partnerships Benelux – Janssen Pharmaceutica

Yannick Van Loubbeeck, Head Discovery and Preclinical Vaccines R&D – GSK

Moderator :

Elisabeth Van Damme, Director External Communication – GSK

13:30-14:30 – Accelerating the development of robust bioprocesses by means of artificial intelligence and in silico models: The next level in the QbD strategy

animated by



Like in many other industries, bioprocesses should now be developed by means of computer-based mathematical and stochastic models. This will allow to accelerate the development of bioprocesses and ensure their long-term robustness as well quality products for the patients. There is a growing number of academic and industry projects that aim at using artificial intelligence, big data analysis, mathematical models delivering predictive tools from the bioreactor to the patient. Having such a strategy for developing models on all aspects from the bioreactor to the end of shelf life present tremendous opportunities since it likely will accelerate the development and optimization of new bioprocesses by leveraging predictive analytics outcomes to support decision-making.

We'll discuss about the opportunities to enter into the “computer-based biological product development” area, but we also mention the various technical challenges such a vision may induce.

The central idea is to show how such a trend brings the Quality By Design (ICH-Q8) strategy to the next level and embrace the Pharmaceutical Quality System (ICH-Q10).

Speaker: Bruno Boulanger, Global Head Statistics and Data Science - Pharmalex

14:00-15:00 – Financing your ambitions: grants, incentives and other sources of financing, including EIB

animated by



As a growing and/or highly innovative company, financing your ambitions may prove to be a challenging process. The landscape of funding opportunities is scattered across different government bodies and agencies, as well as across various types of incentives and instruments.

During this round table you will be guided through the broad spectrum of relevant grants, incentives, and other financing solutions, both at a Belgian and European level, including the EIB financial instruments.

Speaker: Pierre Demoulin, Grants & Incentives Manager - PWC

15:00-16:00 – Life Sciences Companies Going Public: what is the best IPO path for European companies?

animated by



Life Sciences CEOs and Boards are often faced with the challenge of selecting the right strategy to do an IPO. Shall they consider a Euronext IPO, a direct US Nasdaq IPO or a two-step approach of Euronext and then Nasdaq? We will discuss the advantages and drawbacks of each approach as well as the minimum requirements for a medtech/biotech company to go public.

Speakers:

Grégoire Franoux, MBA, Head of Life Sciences Corporate Finance & Equity Capital Markets – Belfius Bank

Fabian Suarez, CFO – Nyxoah

Benoit Van den Hove, Head of Listing Belgium/Luxembourg – Euronext

15:00-16:00 – ESG and sustainable innovation: why is this the only way up for an enhanced performance?

animated by



“Innovate or die”: is the answer to this recurring question compatible with sustainable development goals? Why and how a well-defined WHY of any company, especially in Life Sciences, can change the key performance indicators and go beyond the usual financial indicators?

During this roundtable, Fabien Mathieu, Partner and Managing Director at Ayming France and co-author of the Ayming Institute book “Profit & Planet, how innovation can help build a better world”, will share his views about how ESG and sustainable innovation are actionable levers to improve business performance of any company in the current circumstances.

The 30-minute lecture, illustrated with inspiring examples taken from our experience with biotechs and pharmaceutical industries, will be followed by a 15-minute debate.

Speaker: Fabien Mathieu, Partner & Managing Director France - Ayming

16:00-17:00 – How can the Flemish and Walloon ecosystems mutually reinforce the Belgian leading position in biopharma?

animated by



Janssen Belgium organizes a round table debate about how the Flemish and the Walloon biopharma ecosystems could reinforce each other to strengthen the position of Belgium globally. This panel exists of Vinciane Gaussin, managing director of Welbio, Baudoin Regout, advisor of Secretary of State Thomas Dermine, Philippe Denoel, Head of external R&D vaccines and Sonja Willems, Strategic Director of Janssen Benelux. The debate will be moderated by an expert.

The panel will deep dive into three important strategic axes: the chase for talent, the chase for innovation and the chase for a supportive environment. The debate aims to identify and discuss the necessary bridges between the Flemish and Walloon ecosystems to strengthen the Belgian position globally as well as internally for the players in the Belgian biopharmaceutical landscape.

With a panel consisting out of top profiles in the biopharmaceutical landscape and an expert moderating the debate, this event has all the ingredients to be very interesting and useful for the concrete development of the ambition of our government, biopharmaceutical companies and other important stakeholders: becoming the Health and Biotech Valley of tomorrow.

Speakers:

Vinciane Gaussin, Managing Director - Welbio

Sonja Willems, Strategic Director - Janssen Benelux

Philippe Denoel, Head of Vaccines External R&D - GSK

Baudouin Regout, Advisor in the Cabinet of Secretary of State Thomas Dermine

Moderator TBC